Cannabinor, a selective cannabinoid-2 receptor agonist, improves bladder emptying in rats with partial urethral obstruction
- PMID:21168864
- DOI: 10.1016/j.juro.2010.09.080
Cannabinor, a selective cannabinoid-2 receptor agonist, improves bladder emptying in rats with partial urethral obstruction
Abstract
Purpose: We studied the effects of chronic treatment with the novel selective cannabinoid 2 receptor agonist cannabinor (Procter & Gamble Pharmaceuticals, Cincinnati, Ohio) on bladder function in conscious rats with partial urethral obstruction and on the functional properties of isolated detrusor muscle.
Materials and methods: A total of 24 female Sprague-Dawley® rats with surgically created partial urethral obstruction received daily intraperitoneal injections of 3 mg/kg cannabinor (12) or saline as controls (12) for 2 weeks. Cystometry was done, the rats were sacrificed and the bladders were prepared for in vitro studies.
Results: Mean ± SEM bladder weight was 0.97 ± 0.15 gm in controls and 0.53 ± 0.08 gm in cannabinor treated rats (p <0.05). There was no difference between the groups in the mean micturition interval, or mean baseline, threshold, flow or maximum pressure. In controls and cannabinor treated rats mean post-void residual volume was 0.28 ± 0.07 and 0.06 ± 0.02 ml, mean micturition compliance was 0.032 ± 0.006 and 0.069 ± 0.016 ml/cm H(2)O, and mean bladder wall force at the start of flow was 950 ± 280 and 1,647 ± 325 mN/gm, respectively (each p <0.05). Nonvoiding contractions were significantly less frequent in cannabinor treated rats than in controls. We noted no difference in carbachol (Sigma®) half maximum concentration between the groups but the carbachol maximum response in detrusor strips from cannabinor treated rats was significantly higher than that in control strips.
Conclusions: In rats with partial urethral obstruction treated daily for 14 days with cannabinor bladder weight was lower, the ability to empty the bladder was preserved and nonvoiding contraction frequency was low compared to those in controls. Detrusor preparations from cannabinor treated rats showed a higher response to nerve stimulation than those from controls. Selective cannabinoid 2 receptor activation may be a novel principle to enable improved bladder function after partial urethral obstruction.
Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Similar articles
- Effects of cannabinor, a novel selective cannabinoid 2 receptor agonist, on bladder function in normal rats.Gratzke C, Streng T, Stief CG, Downs TR, Alroy I, Rosenbaum JS, Andersson KE, Hedlund P.Gratzke C, et al.Eur Urol. 2010 Jun;57(6):1093-100. doi: 10.1016/j.eururo.2010.02.027. Epub 2010 Mar 1.Eur Urol. 2010.PMID:20207474
- Intradetrusor botulinum neurotoxin A (BoNT-A) injections decrease bladder fibrosis secondary to partial urethral obstruction in the male rat model.Tinay I, Tanidir Y, Cikler E, Cetinel S, Tarcan T.Tinay I, et al.Neurourol Urodyn. 2012 Apr;31(4):564-70. doi: 10.1002/nau.21248. Epub 2012 Jan 24.Neurourol Urodyn. 2012.PMID:22275224
- Antimuscarinic drug inhibits detrusor overactivity induced by topical application of prostaglandin E2 to the urethra with a decrease in urethral pressure.Yokoyama O, Miwa Y, Oyama N, Aoki Y, Ito H, Akino H.Yokoyama O, et al.J Urol. 2007 Nov;178(5):2208-12. doi: 10.1016/j.juro.2007.06.044. Epub 2007 Sep 17.J Urol. 2007.PMID:17870108
- β-adrenoceptor agonist effects in experimental models of bladder dysfunction.Michel MC, Ochodnicky P, Homma Y, Igawa Y.Michel MC, et al.Pharmacol Ther. 2011 Jul;131(1):40-9. doi: 10.1016/j.pharmthera.2011.03.014. Epub 2011 Apr 12.Pharmacol Ther. 2011.PMID:21510978Review.
- Urinary bladder function and drug development.Ferguson D, Christopher N.Ferguson D, et al.Trends Pharmacol Sci. 1996 Apr;17(4):161-5. doi: 10.1016/0165-6147(96)81593-8.Trends Pharmacol Sci. 1996.PMID:8984744Review.
Cited by
- Treatment with a cannabinoid receptor 2 agonist decreases severity of established cystitis.Wang ZY, Wang P, Bjorling DE.Wang ZY, et al.J Urol. 2014 Apr;191(4):1153-8. doi: 10.1016/j.juro.2013.10.102. Epub 2013 Oct 29.J Urol. 2014.PMID:24184363Free PMC article.
- Activation of cannabinoid receptor 2 inhibits experimental cystitis.Wang ZY, Wang P, Bjorling DE.Wang ZY, et al.Am J Physiol Regul Integr Comp Physiol. 2013 May 15;304(10):R846-53. doi: 10.1152/ajpregu.00585.2012. Epub 2013 Mar 20.Am J Physiol Regul Integr Comp Physiol. 2013.PMID:23515618Free PMC article.
- Indole compounds withN-ethyl morpholine moieties as CB2 receptor agonists for anti-inflammatory management of pain: synthesis and biological evaluation.Li J, Ji J, Xu R, Li Z.Li J, et al.Medchemcomm. 2019 Sep 17;10(11):1935-1947. doi: 10.1039/c9md00173e. eCollection 2019 Nov 1.Medchemcomm. 2019.PMID:32952995Free PMC article.
- The Structure-Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation.Bow EW, Rimoldi JM.Bow EW, et al.Perspect Medicin Chem. 2016 Jun 28;8:17-39. doi: 10.4137/PMC.S32171. eCollection 2016.Perspect Medicin Chem. 2016.PMID:27398024Free PMC article.
- Pharmacology of the lower urinary tract.Hennenberg M, Stief CG, Gratzke C.Hennenberg M, et al.Indian J Urol. 2014 Apr;30(2):181-8. doi: 10.4103/0970-1591.126903.Indian J Urol. 2014.PMID:24744518Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical